ORMP (Oramed Pharmaceuticals) Debt-to-Asset : 0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ORMP Oramed Pharmaceuticals Inc ORMP
32 GF Score
Price $4.79
! 5 Warning Signs
View Full Analysis

What is Oramed Pharmaceuticals Debt-to-Asset?

Oramed Pharmaceuticals ORMP 32 Debt-to-Asset is 0.00 as of Jun. 2026. GuruFocus rates ORMP with a GF Score™ of 32/100. The stock has 5 warning signs investors should review.

Oramed Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $0.25 Mil. Oramed Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $0.48 Mil. Oramed Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was $369.64 Mil. Oramed Pharmaceuticals's debt to asset for the quarter that ended in Jun. 2026 was 0.00.

Oramed Pharmaceuticals  (NAS:ORMP) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Oramed Pharmaceuticals Debt-to-Asset Related Terms

Oramed Pharmaceuticals Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Oramed Pharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oramed Pharmaceuticals Debt-to-Asset Chart

Oramed Pharmaceuticals Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.01 0.23 0.00 0.00

Oramed Pharmaceuticals Quarterly Data
Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.00 0.00 0.00 0.00

ORMP vs CAMP, PYXS, ALEC: Debt-to-Asset Comparison

For the Biotechnology subindustry, Oramed Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oramed Pharmaceuticals Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Oramed Pharmaceuticals's Debt-to-Asset falls into.


ORMP
32GF Score
Oramed Pharmaceuticals Inc ORMP
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oramed Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Oramed Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.285 + 0.54) / 230.864
=0.00

Oramed Pharmaceuticals's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.249 + 0.484) / 369.643
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.00 mean?
Oramed Pharmaceuticals (ORMP) has a Debt-to-Asset of 0.00 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Oramed Pharmaceuticals and its competitors.
Is Oramed Pharmaceuticals' Debt-to-Asset too high?
Oramed Pharmaceuticals' current Debt-to-Asset is 0.00. Overall, Oramed Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Oramed Pharmaceuticals' Debt-to-Asset compare to CAMP and PYXS?
Oramed Pharmaceuticals' Debt-to-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Oramed Pharmaceuticals and its competitors. Oramed Pharmaceuticals's current Debt-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oramed Pharmaceuticals stock overvalued right now?
Oramed Pharmaceuticals (ORMP) has a current Debt-to-Asset of 0.00. The current Debt-to-Asset is 0.00. Oramed Pharmaceuticals' overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Oramed Pharmaceuticals (ORMP), the current Debt-to-Asset is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oramed Pharmaceuticals Business Description

Other Exchanges ORMP:IsraelOJU1:Germany
Address 1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
32GF Score

Get the complete analysis for ORMP

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.79
Price